Crinetics Pharmaceuticals, having secured FDA approval for Palsonify, an oral once-daily treatment for acromegaly, is positioned to compete with established injectable therapies from pharma giants such as Novartis and Ipsen. Clinical trials confirm Palsonify’s efficacy in lowering growth hormone levels and a manageable safety profile. The company’s stock surged following the news, exemplifying investor confidence in this competitive entry to the rare endocrine disorder therapeutic space.